Regenerative medicine uses clinical procedures to repair or replace damaged or diseased tissues and organs, versus some traditional therapies that just treat symptoms.
To realize the vast potential of tissue engineering and other techniques aimed at repairing damaged or diseased tissues and organs, the University of Pittsburgh School of Medicine and UPMC established the McGowan Institute for Regenerative Medicine. The McGowan Institute serves as a single base of operations for the University’s leading scientists and clinical faculty working to develop tissue engineering, cellular therapies, and artificial and biohybrid organ devices.
The McGowan Institute is the most ambitious regenerative program in the nation, coupling biology, clinical science, and engineering. Success in our mission will impact patients’ lives, bring economic benefit, serve to train the next generation of researchers, and advance the expertise of our faculty in the basic sciences, engineering, and clinical sciences. Our efforts proudly build upon the pioneering achievements of the Thomas E. Starzl Transplantation Institute.
While there are certain select therapies based on regenerative medicine principles now in clinical use, much work lies ahead to realize the potential of this growing field. Advances in the underlying science, engineering strategies to harness this science, and successful commercial activities are all required to bring new therapies to patients.
McGowan Institute for Regenerative Medicine
450 Technology Drive
Pittsburgh, PA 15219
The McGowan Institute sponsors a podcast series on regenerative medicine. Listen to some of the world's leading regenerative medicine researchers and physicians talk about their work.
There is new data that show the HeartMate 3™ heart pump extends survival of advanced heart failure patients by at least five years, providing a clear life-saving option for people battling later stage heart disease. The HeartMate 3 heart pump Full MagLev™ technology was developed by researchers (James Antaki, PhD; Harvey Borovetz, PhD) at the McGowan Institute for Regenerative Medicine. When McGowan Institute affiliated faculty member Robert Kormos, MD (pictured), a cardiothoracic surgeon, began his career 30 years ago, he would dream of extending the lives of his patients who were often battling advanced heart failure. Now, serving as division vice president of medical device company Abbott, that is no longer a dream.
Cell-free plasma hemoglobin (PHb) is now recognized as a common and problematic sequela of extracorporeal therapies (ECT) such as cardiopulmonary bypass (CPB) and extracorporeal membrane oxygenation (ECMO) with contributions to organ injury such as acute kidney injury. The goal of new research is to develop a novel and selective extracorporeal hemadsorption device capable of removing PHb during all forms of ECT. The prototype will be evaluated for compatibility with ECT, the capability to effectively remove PHb, and the ability to ameliorate ECT-related kidney injury.
The University of Pittsburgh School of Medicine and UPMC have selected McGowan Institute for Regenerative Medicine affiliated faculty member MaCalus Hogan, MD, MBA (pictured), as the new David Silver Professor and Chair of Pitt’s Department of Orthopaedic Surgery and Chair of Orthopaedic Surgery at UPMC. Dr. Hogan will begin his tenure in the position once held by Freddie Fu, MD, whose legacy as department chair from 1998 to 2021 attained a stellar international reputation for leading key scientific and clinical innovations. The department grew into one of the most ethnic- and gender-diverse orthopaedic departments in the nation, preparing dozens of physicians to become leaders in orthopaedics at universities and hospitals throughout the world. Dr. Fu passed away in September 2021.
McGowan Institute for Regenerative Medicine affiliated faculty member Joseph Glorioso III, PhD (pictured), is a Professor in the Department of Microbiology and Molecular Genetics at the University of Pittsburgh School of Medicine and holds a secondary appointment in the Department of Human Genetics, University of Pittsburgh Graduate School of Public Health. He is also a co-founder of the genome writing company, Replay, where he is the inventor of the company’s synHSV™ technology and is the Senior Advisor for Gene Therapy Programs.